With over 35 years of clinical experience , our Idaho-based clinic has helped thousands of patients near Meridian, Boise, and Nampa lose weight and reclaim their wellness
Obtaining these values objectively takes the guess- work out of knowing if one or more of these factors may be impeding your body composition goals
In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
Legal Disclaimer: *These statements have not been evaluated by the FDA
Over a 68-week period, participants experienced an average weight loss of around 15% of their body weight
Clinical trials vs real-world results What the clinical trials show The landmark SURMOUNT-5 trial published in 2025 compared these medications directly at standard maximum doses: 1 Mounjaro (tirzepatide 15 mg) produced 20.2% average weight loss Wegovy (semaglutide 2.4 mg) produced 13.7% average weight loss The 6.5 percentage point difference was statistically significant This trial used the maximum approved doses at the time (Mounjaro 15 mg, Wegovy 2.4 mg) and lasted 72 weeks
